Eli Lilly’s newly launched obesity pill Foundayo recorded 1,390 prescriptions in its first week on the U.S. market, according to analyst data cited by Reuters, highlighting an early but measured uptake as the drug enters a highly competitive weight loss market.
The prescriptions cover the week ended April 10, shortly after the pill’s April 1 regulatory approval and phased rollout through telehealth platforms and retail pharmacies. Early distribution began via Lilly’s direct channel before broader availability expanded across pharmacies in the following days.
The launch figure places Foundayo behind some competing obesity treatments in initial uptake. Novo Nordisk’s oral Wegovy, for example, recorded more than 3,000 prescriptions in its first few days on the U.S. market, reflecting strong early demand in the rapidly growing GLP 1 drug category.
Analysts say early prescription data for new obesity drugs often fluctuates significantly in the first weeks due to phased distribution, insurance coverage delays, and uneven adoption across retail, telehealth, and mail order channels. Lilly itself has cautioned that capture rates can be volatile at launch.
The broader obesity drug market has become one of the most closely watched segments in global pharmaceuticals, with companies racing to expand from injectable therapies to more convenient oral options. Foundayo is part of this shift, aiming to offer patients a once daily pill alternative that could broaden access and improve adherence over time.
Investors are also tracking early demand closely, as prescription momentum is seen as an indicator of long term commercial potential in a market projected to become a multibillion dollar category over the next decade.
Despite the modest initial numbers, analysts note that it is still very early in the rollout phase, and prescription volumes could accelerate as awareness increases and insurance coverage expands.
Leave a comment